Trial
NCT01945281
Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Candidiasis, Invasive
Intervention
Caspofungin
Why stopped
Operational feasibility with low recruitment due to changing epidemiology of disease
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-25